ArticleBrain and behavior2025
Serum 25-Hydroxyvitamin D3 Status in Adolescents With Anxiety Disorders: A Case-Control and Vitamin D Supplementation Substudy.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum 25-Hydroxyvitamin D3 Status in Adolescents With Anxiety Disorders: A Case-Control and Vitamin D Supplementation Substudy.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveTo investigate the correlation between serum 25-hydroxyvitamin D3 (25-(OH)D3) levels and anxiety disorders in adolescents, and to assess the potential impact of vitamin D status on pediatric anxiety disorders, thereby providing clinical evidence for diagnosis and treatment.
methodsThis study included 124 adolescents with anxiety disorders who visited the pediatric outpatient department of Jingzhou First People's Hospital from January 2020 to December 2022 as the experimental group and 131 healthy adolescents who underwent physical examinations during the same period as the control group. Serum 25-(OH)D3 levels were compared between the two groups. Simple linear regression analysis was conducted to evaluate the predictive capacity of 25-(OH)D3 levels on anxiety scores in the experimental group. Additionally, 86 adolescents with anxiety disorders and 25-(OH)D deficiency or insufficiency in the experimental group received vitamin D supplementation for 12 weeks, and changes in anxiety scores before and after supplementation were analyzed to assess the effect of 25-(OH)D3 levels on anxiety disorders.
resultsThe mean serum 25-(OH)D3 level in the experimental group [(16.48 ± 6.53) ng/ml] was significantly lower than that in the control group [(22.95 ± 7.25) ng/ml], with a statistically significant difference (p < 0.05). The prevalence of vitamin D deficiency and insufficiency was higher in the experimental group (69.35%) than in the control group (36.64%), with a statistically significant difference (p < 0.05). Furthermore, in the experimental group, anxiety scores were negatively correlated with serum 25-(OH)D
conclusionVitamin D deficiency may represent a potential risk factor for anxiety disorders in adolescents and demonstrate some predictive value for these conditions. Vitamin D supplementation could potentially alleviate anxiety symptoms in adolescents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.